Neodymium-YAG Laser in Transitional Cell Cancer of the Bladder with Emphasis on Outpatient Potential

Publisher Website
Google Scholar
Abstract
With ever-increasing medical costs in the United States, the neodymium-YAG laser has afforded urologists the opportunity to treat the vast majority of patients with superficial transitional cell carcinoma of the bladder (T0, Tl, T2) as outpatients. This has significantly decreased medical costs as well as patient loss of income. Seventysix patients with superficial transitional cell carcinoma of the bladder were treated solely with the neodymium-YAG laser and followed for at least 2 years. No patient received ancillary treatment, chemotherapy, or radiation. Forty-eight patients (63%) had no evidence of recurrent tumors when followed for 2 years or longer. Twenty-eight patients (37%) had recurrent tumors. Only 3 patients (4%) had an increase in stage. There were no major complications in this group of patients. Seventy percent of the patients were treated as outpatients or 1-day hospital admissions.

This publication has 0 references indexed in Scilit: